The latest T1D content
Research that matters
Our daily questions
Continue with Google
Continue with Facebook
Demeterco-Berggren, C, Jacobsen, L, Guttmann-Bauman, I, Ospelt, E, Smego, A, Hannon, T, Aleppo, G, Chouhary, A, Wong, J, Ebekozien, O
Background: The interest in type 1 diabetes (T1D) screening has been ignited since the U.S. FDA approval of teplizumab (November 2022) for the delay of T1D onset among those at risk. We aimed to identify the real-world status of autoantibody screening and teplizumab administration readiness among T1DX-QI centers.
Methods: A survey was administered from July to September 2023 to 55 centers participating in the T1DX-QI. Descriptive analysis was completed.
Results: Fifty of 55 centers (91%) completed the survey; 68% were pediatric and 32% were adult centers. The majority of centers (68%) had not made any substantive changes to T1D screening practices. Of the centers that had adjusted their screening practices, most developed more specific guidelines and workflows to screen first-degree relatives of people with T1D. Pediatric centers were more prepared to administer teplizumab, with the majority developing and implementing a protocol, in comparison to adult centers (Figure 1a). There is no standard screening laboratory among adult and pediatric centers (Figure 1b).
Conclusions: It is necessary to explore the barriers to implementing T1D screening and teplizumab administration in the real-world setting as the majority of centers are still in the early stages of bringing this to clinical care.
